CORETAG Holding AG is an oncology biotechnology company that develops radioligand-based diagnostic and therapeutic approaches for solid tumors. Its work centers on the Tumor Necrosis Targeting Platform® and the candidates CyanTag® and CyanCore® for diagnosis, therapy, and treatment monitoring.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of targeted radioligands and radiopharmaceuticals based on a proprietary Tumor Necrosis Targeting Platform; includes diagnostics, therapy and treatment-response monitoring in solid tumors.
Radioligand therapy pipeline
Clinical and preclinical radioligand programs for difficult-to-treat solid tumors, including CyanTag®, CyanCore®, HQ-4® and further pipeline expansions with diagnostic and therapeutic isotopes.
Comparisons
CORETAG Holding AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank CORETAG Holding AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once CORETAG Holding AG has claimed this profile, we'll publish editorial articles and case studies here together.